ArticleBMC cancer2025
Antiresorptive agents in the management of bone metastatic disease: a multicenter mixed-methods study in Palestinian clinical practice.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntiresorptive agents are recommended for patients with bone metastatic disease in order to treat hypercalcemia of malignancy, to reduce skeletal-related events, and to alleviate bone pain. This study was conducted to describe prescribing practices for antiresorptive agents among patients with metastatic bone disease within the Palestinian healthcare system.
methodsWe conducted a multicenter, mixed-method study that combined a retrospective analysis of prescription data for antiresorptive agents in patients with metastatic bone disease with a cross-sectional survey of the views and opinions of oncologists and orthopedists practicing within the Palestinian healthcare system regarding the benefits and risks associated with these agents.
resultsIn this study, 239 patients with metastatic bone disease were included. The median age of the patients was 61.0 [52.0-69.0] years, the median duration of cancer was 3.0 [1.0-6.0] years, and the median duration of bone metastatic disease was 1.0 [1.0-3.0] years. Of these patients, 139 (58.2%) received antiresorptive agents. Patients prescribed antiresorptive agents were more likely to experience hypoglycemia (p-value = 0.005) compared to those not receiving these agents. The duration of antiresorptive agent use was positively associated with the duration of cancer (Spearman's rho = 0.38, p-value < 0.001) and with the duration of bone metastatic disease (Spearman's rho = 0.45, p-value < 0.001). Among the surveyed oncologists and orthopedists, 40% reported that prescribing antiresorptive agents for patients with bone metastatic disease was routine practice, while 60% indicated that they would recommend antiresorptive agents even if the patient experienced minimal or no pain. Moreover, 70% of the oncologists and orthopedists preferred initiating treatment with zoledronic acid as the first-line antiresorptive agent for patients with bone metastases.
conclusionOur study revealed significant variability in the prescribing patterns and dosing schedules of antiresorptive agents, highlighting the need to adopt standardized, evidence-based protocols to enhance patient outcomes and optimize resource allocation in managing bone metastatic disease. Furthermore, future research should focus on evaluating patient-centered outcomes, long-term safety profiles, and the impact of educational and regulatory changes on practice patterns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.